Results 81 to 90 of about 3,116,614 (307)

c‐Rel–dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis

Hepatology, EarlyView., 2022
In response to genotoxic injury, c‐Rel upregulates ATM‐Chk2‐p53 pathway DNA damage proteins to limiting hepatocarcinogenesis. Abstract Background and Aims Hepatocellular carcinoma (HCC) is a leading cause of cancer‐related death. The NF‐κB transcription factor family subunit c‐Rel is typically protumorigenic; however, it has recently been reported as a
Jack Leslie, Jill E. Hunter, Amy Collins, Amelia Rushton, Lauren G. Russell, Erik Ramon‐Gil, Maja Laszczewska, Misti McCain, Marco Y. W. Zaki, Amber Knox, Yixin Seow, Laura Sabater, Daniel Geh, Neil D. Perkins, Helen L. Reeves, Dina Tiniakos, Derek A. Mann, Fiona Oakley   +17 more
wiley   +1 more source

Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma. [PDF]

, 2014
BackgroundIncreasing studies implicate cancer stem cells (CSCs) as the source of resistance and relapse following conventional cytotoxic therapies. Few studies have examined the response of CSCs to targeted therapies, such as tyrosine kinase inhibitors ...
Ames, Erik, Borys, Dariusz, Canter, Robert J, Chen, Mingyi, Grossenbacher, Steven K, Li, Chin-Shang, Mac, Stephanie, Monjazeb, Arta M, Murphy, William J, Sayers, Thomas J, Smith, Rachel C, Tellez, Joe   +11 more
core   +2 more sources

HSP90β Impedes STUB1‐Induced Ubiquitination of YTHDF2 to Drive Sorafenib Resistance in Hepatocellular Carcinoma

Advancement of science, 2023
YTH domain family 2 (YTHDF2) is the first identified N6‐methyladenosine (m6A) reader that regulates the status of mRNA. It has been reported that overexpressed YTHDF2 promotes carcinogenesis; yet, its role in hepatocellular carcinoma (HCC) is elusive ...
Yuning Liao, Yuan Liu, Cuifu Yu, Q. Lei, Jia Hua Cheng, Weiyao Kong, Yuanhui Yu, Xuefen Zhuang, Wenshuang Sun, Shusha Yin, Gengxi Cai, Hongbiao Huang   +11 more
semanticscholar   +1 more source

Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells [PDF]

Current Oncology, 2021
Sorafenib, an oral multi-tyrosine kinase inhibitor, has been the first-line therapy for the treatment of patients with advanced HCC, providing a survival benefit of only three months in approximately 30% of patients. Cancer stem cells (CSCs) are a rare tumour subpopulation with self-renewal and differentiation capabilities, and have been implicated in ...
Ritu Shrestha, Kim R. Bridle, Lu Cao, Darrell H. G. Crawford, Aparna Jayachandran   +4 more
openaire   +3 more sources

Engineered extracellular vesicles mediated CRISPR-induced deficiency of IQGAP1/FOXM1 reverses sorafenib resistance in HCC by suppressing cancer stem cells

Journal of Nanobiotechnology, 2023
Sorafenib resistance poses therapeutic challenges in HCC treatment, in which cancer stem cells (CSCs) plays a crucial role. CRISPR/Cas9 can be utilized as a potential technique to overcome the drug resistance.
Cong He, Doulathunnisa Jaffar Ali, Y. Qi, Yumin Li, Beicheng Sun, Rui Liu, Bo Sun, Zhongdang Xiao   +7 more
semanticscholar   +1 more source

Multiple Mechanisms Mediate Resistance to Sorafenib in Urothelial Cancer [PDF]

International Journal of Molecular Sciences, 2014
Genetic and epigenetic changes in the mitogen activated protein kinase (MAPK) signaling render urothelial cancer a potential target for tyrosine kinase inhibitor (TKI) treatment. However, clinical trials of several TKIs failed to prove efficacy. In this context, we investigated changes in MAPK signaling activity, downstream apoptotic regulators and ...
Judith Knievel, Wolfgang Schulz, Annemarie Greife, Christiane Hader, Tobias Lübke, Ingo Schmitz, Peter Albers, Günter Niegisch   +7 more
openaire   +3 more sources

Protocol to screen for Sorafenib resistance regulators using pooled lentiviral shRNA library and a Sorafenib-resistant hepatocellular carcinoma cell model

STAR Protocols, 2023
Approaches to study therapy resistance in HCC (hepatocellular carcinoma) are limited, especially when using HCC models in vitro. Here, we present a protocol to establish an in vitro Sorafenib-resistant human HCC cell model and conduct an shRNA-mediated synthetic lethal screen in established Sorafenib-resistant HCC cell lines to identify critical ...
Ruize Gao, Fengyuan Tang, Gerhard Christofori   +2 more
openaire   +3 more sources

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib [PDF]

, 2016
ARQ 197-215 was a randomized placebo-controlled phase II study testing the MET inhibitor tivantinib in second-line hepatocellular carcinoma (HCC) patients. It identified tumor MET as a key biomarker in HCC.
Abbadessa, Giovanni, Borbath, Ivan, Daniele, Bruno, De Toni, Enrico N, Gasbarrini, Antonio, Lamar, Maria E, Lencioni, Monica, Miles, Steven, Personeni, Nicola, Porta, Camillo, Rimassa, Lorenza, Salvagni, Stefania, Santoro, Armando, Schwartz, Brian E, Shuster, Dale, Trojan, Jörg, Van Laethem, Jean-Luc, Van Vlierberghe, Hans, Wang, Yunxia, Weiss, Alan   +19 more
core   +4 more sources

Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma

Journal of experimental & clinical cancer research : CR, 2022
Background Drug resistance to sorafenib greatly limited the benefits of treatment in patients with hepatocellular carcinoma (HCC). MicroRNAs (miRNAs) participate in the development of drug resistance.
Yuanjun Lu, Y. Chan, H. Tan, Cheng Zhang, W. Guo, Yu Xu, Rakesh Sharma, Zhe-Sheng Chen, Yi Zheng, Ning Wang, Yibin Feng   +10 more
semanticscholar   +1 more source

Multidrug Resistance Protein 2 Implicates Anticancer Drug-Resistance to Sorafenib

Biological and Pharmaceutical Bulletin, 2011
Sorafenib and sunitinib is a small molecule inhibitor of certain receptor tyrosine kinases, and have improved outcomes for patients with advanced renal cell carcinoma. Inhibitory concentration of 50% cell growth of sorafenib significantly rose to 6.4-fold in a multidrug resistance protein 2 (MRP2) transfected cell line versus control cell line.
Yoshihiko, Shibayama, Kou, Nakano, Hiroshi, Maeda, Miyuki, Taguchi, Ryuji, Ikeda, Mitsuru, Sugawara, Ken, Iseki, Yasuo, Takeda, Katsushi, Yamada   +8 more
openaire   +3 more sources